Not exact matches
Clinical trials of GlaxoSmithKline's diabetes
drug Avandia (rosiglitazone) and Merck's anti-inflammatory Vioxx (
rofecoxib) revealed an elevated cardiac risk from the
drugs, but relevant findings were held back from regulators or never published.
Known as a COX - 2 inhibitor, Bextra belongs to the same class of
drugs as
rofecoxib (Vioxx), which manufacturer Merck yanked from pharmacy shelves last September after safety risks appeared (SN: 10/30/04, p. 286: Available to subscribers at COX - 2 inhibitor pulled off market.).
The COX - 2 inhibitor known as
rofecoxib was removed from the market in 2004 after a study revealed that cardiovascular disease risk was increased by the
drug.